Results 161 to 170 of about 3,116,614 (307)
The paradox of cancer genes in non-malignant conditions: implications for precision medicine. [PDF]
, 2020 Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures.
Adashek, Jacob J +3 more
core
Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents [PDF]
, 2018 Background/Aim: The expression of IL-8 and FGFR has been related to prognosis and pathological features in renal cell carcinoma. We investigated the relationship between IL-8 and FGFR and the outcome in metastatic renal cell carcinoma (mRCC) patients ...
Carella, Consiglia +7 more
core +1 more source
iNew Medicine, EarlyView.ABSTRACT Hepatocellular carcinoma (HCC) represents a significant global health issue, with the PD‐1/PD‐L1 axis serving a pivotal target for immunotherapy in this malignancy. However, a comprehensive bibliometric analysis of PD‐1/PD‐L1 research in HCC is lacking.
Xingyu Zhu +4 more
wiley +1 more source
Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus
Translational Oncology, 2018 Hepatitis B virus (HBV) targets the liver and is a major driver for liver cancer. Clinical data suggest that HBV infection is associated with reduced response to treatment with the multi-kinase inhibitor sorafenib, the first available molecularly ...
Dvora Witt-Kehati +4 more
doaj +1 more source
Living in interesting times - Challenging protein metabolism in the era of the epidemiological shift [PDF]
, 2016 The recently released results of the Global Burden of Disease, Injuries, and Risk Factor study 2013 reveal that during the past 23 years, metabolic and behavioral risk factors, including high BMI, increased their impact on global mortality and disability-
Laviano, Alessandro
core +1 more source
Journal of Intelligent Medicine, EarlyView.Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan +3 more
wiley +1 more source
Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF [PDF]
, 2010 Background Cumulative light exposure is significantly associated with progression of age-related macular degeneration (AMD). Inhibition of vascular endothelial growth factor is the main target of current antiangiogenic treatment strategies in AMD ...
Alge, C. S. +7 more
core +3 more sources
Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma.
Aging, 2020 For nearly a decade, sorafenib has served as a first-line chemotherapeutic drug for the treatment of hepatocellular carcinoma (HCC), but it displays only limited efficacy against advanced drug-resistant HCC. Regorafenib, the first second-line drug approved for treatment after sorafenib failure, can reverse resistance to sorafenib.
Zhu, Qiankun +7 more
openaire +2 more sources
Journal of Periodontology, EarlyView.Abstract Background Hypoxia modulates inflammation and oxidative stress through hypoxia‐inducible factor‐1α (HIF‐1α). Ferroptosis, an iron‐dependent cell death process, is regulated by glutathione peroxidase‐4 (GPX4) and involves lipid peroxidation markers like malondialdehyde (MDA).
Büşra Yılmaz +5 more
wiley +1 more source
Focal adhesion kinase: Insight into molecular roles and functions in hepatocellular carcinoma [PDF]
, 2017 Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Due to the high incidence of post-operative recurrence after current treatments, the identification of new and more effective drugs is required.
Alisi, Anna +4 more
core +2 more sources